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Problem: The Human Papillomavirus (HPV) is a group of more than 150 viruses that are a 
causative agent in many types of cancers. This virus can be linked to cervical cancer, vulvar 
cancer, vaginal cancer, penile cancer, anal cancer, and throat cancer. There are currently three 
approved vaccines to prevent the spread of HPV that are known to be associated to these cancers. 
The number of young adults in the United States that receive HPV vaccine is low. One of the 
reasons identified for not receiving the HPV vaccine is a knowledge deficit related to the disease 
and the vaccine.  
 
Project Aim: The aim of this quality improvement project will be to increase the number of 
HPV vaccines given to young adults (ages 18-26) through an educational pamphlet related to 
HPV and the HPV vaccines. The Project Director assumes that providing an educational 
pamphlet to young adults before they see their health care provider will increase the number of 
HPV vaccines administered at in a clinic setting (ComCare). 
 
Project Method: This quality improvement project was conducted at ComCare in Salina, 
Kansas. An educational pamphlet about HPV and the HPV vaccine was constructed from the 
literature and input from four healthcare professionals, including three nurse practitioners and 
one physician. A five-question pre-survey concerning the HPV vaccine and patient 
demographics was provided to the 10 healthcare providers at ComCare. Providers were given 
one week to complete the surveys. The pamphlets were then made available to young adult 
patients at this clinic for a six-week period by being placed in the waiting room, as well as in 
patient care areas. After the six-weeks were completed, the providers were given a six-question 
post-survey to determine the effectiveness of the educational pamphlets.  
 
Results: Nine out of the 10 providers at ComCare completed the pre-survey and eight out of 10 
providers completed the post-survey. The post surveys showed a slight increase in the number of 
patients who had received the vaccine as well as the number of patients who initiated the vaccine 
each week. At ComCare, 89% of providers indicated that an educational deficit was why patients 
refused the HPV vaccine. There were 62% of providers at ComCare thought that the pamphlets 
were beneficial in their care, related to HPV, for young men and women age 18 to 26 in their 
clinic.  
 
Conclusion: Pamphlets containing educational information on HPV and HPV vaccines in a 
clinic setting appears to be useful in increasing the number of HPV vaccines administered. 
Providers in the clinic setting identified the largest factor related to not vaccinating against HPV 
was an educational deficit. Further studies should be conducted in additional clinics to determine 
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if educational pamphlets are beneficial in increasing the number of young adults that obtain the 
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Human papillomavirus (HPV) is a group of more than 150 related viruses that are 
transmitted through direct skin-to-skin contact, usually sexual, with an infected person (Center 
for Disease Control and Prevention [CDC], 2015). The virus is most commonly spread through 
vaginal or anal sex, but can be transmitted following nonpenetrative sexual activity. Currently, 
one in four Americans are infected with HPV (CDC, 2015). The most at risk group for HPV are 
sexually active women, under the age of 25, but many sexually active men and women get HPV 
at some point in their lives (Palefsky, 2016).  
HPV is the causative agent in cell changes that result in genital warts and several cancers. 
Over 27,000 women and men are affected by a cancer caused by HPV annually. This virus can 
be linked to almost all cervical cancers, 91% of anal cancers, 75% of vaginal cancers, 72% of 
throat cancers, 69% of vulvar cancers, and 63% of penile cancers (CDC, 2015). Many of these 
cancers do not have signs or symptoms until they are in the advanced stages making treatment 
difficult. Statistics from the CDC (2015) show that from 2005-2009 there were 3,968 deaths 
annually due to cervical cancer, which were nearly all related to HPV. Currently, HPV can be 
identified at the causative agent in half a million deaths worldwide every year (Westrich, 
Warren, Pyeon, 2016). 
Statement of the Problem 
HPV is a group of viruses that currently has one of the highest incidence rates when 
compared with other STIs in the United States. It is estimated that there are nearly 20 million 
new sexually transmitted diseases (STIs) in the United States annually. HPV attains for nearly 
50% of these newly acquired STIs. Although about 90% of new HPV infections will 
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spontaneously resolve within two years, the care for the remaining 10% is rather costly due to 
the expense of treating HPV related cancers (World Health Organization, 2016). 
The medical costs to care for individuals who acquire a new STI totals around $16 
billion. Annual costs for preventing and treating HPV associated diseases was estimated to be 
$8.0 billion in 2010 (Chesson, Ekwueme, Saraiya, Watson, Lowy, & Markowitz, 2012). There is 
currently no cure for the HPV virus thus; one method to address this issue is through prevention 
of the virus. 
There are currently three different multi-dose vaccine series available that provide 
immunity against HPV strands that are known to cause multiple cancers and genital wart 
(Smulian, Mitchell, & Stokley, 2016). Unfortunately, the CDC (2015) found that HPV 
vaccination initiation and completion rates are lower than desired by healthcare professionals. 
This leaves many people at risk for a multitude of cancers and genital warts. Low rates of 
immunizations, also increase the financial burden related to this disease.   
The World Health Organization (WHO) (2016) recommends a comprehensive approach 
to preventing and controlling HPV related illnesses. This includes community education, social 
mobilization, vaccination, screening, treatment, and palliative care. It is important for healthcare 
providers to educate patients and develop ways to decrease the number of newly acquired HPV 
infections. Primary prevention interventions, such as vaccinations, are recommended prior to 
exposure and acquisition of HPV. It can also decrease the financial constraints observed 
throughout the American healthcare system due to HPV incidences and related illnesses. 
Literature Review 
A literature review was conducted from August 2016 to March 2017 to determine 
common causes of not receiving the vaccination and interventions that help increase the 
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initiation of the HPV vaccine series. The databases that were search included PubMed and 
CINAHL. The keywords searched included human papillomavirus, HPV, vaccine, interventions, 
and increase uptake. The search was limited to English articles that were published between 
2011 and 2016. The articles title and abstracts were reviewed to determine relevance to the study 
for inclusion into the literature review section.  
Data from the articles that were relevant were placed on the matrix in Appendix A. The 
matrix contains the citation, level of evidence, sample/setting, data collection/interventions, key 
findings, limitations, and summary of findings. The matrix includes 16 articles total.  
Pathophysiology of HPV 
 HPV is a small double-stranded deoxyribonucleic acid (DNA) virus that infects the basal 
epithelial cells of the skin and mucosal membranes and can cause different types of warts and 
benign or malignant tumors (Sabeena, Bhat, Kamath, & Arunkumar, 2017; Westrich, Warren, & 
Pyeon, 2016). The transmission of the virus is species specific and most commonly transmitted 
through sexual contact (Sabeena, et al., 2017). For HPV to initiate infection, it must translocate 
across skin and mucous membranes. After the virus invades the host, it must withstand multiple 
defense mechanisms of the body. To do this, HPV interferes with multiple cellular pathways to 
evade the host immune response. 
Host Defense 
Mucous membranes pose a major physical barrier to the virus due to the secretion of 
viscous protective fluid and antimicrobial peptides (Sabeena, et al., 2017). Once the virus has 
invaded a host cell, innate pathogen sensors recognize the pathogen. When the pathogen has 
been detected, innate immune cells, such as dendritic, Langerhans, natural killer, and natural 
killer T cells, move to the HPV-infected environment (Westrich, Warren, & Pyeon, 2016). The 
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secretion of various cytokines, interferon-α (IFN-α), interlukin-6 (IL-6), tumor necrosis factor α 
(TNF-α), and IL-8, occurs when the innate immune cells are activated. The host T cell responses 
are required for elimination of HPV, but antibody titers from natural immunity are usually too 
low to protect the host against the virus (Westrich, Warren, & Pyeon 2016). 
HPV Invasion 
 After the virus invades the host cell, the virus enters the nucleus. The virus then alters the 
host DNA methylation process, which is responsible for distinct gene expression patterns. The 
virus then manipulates host transcription (Mallen-St Clair, Alani, Wang, & Srivatsan, 2016). 
The host immune response is altered due to expression of HPV oncoproteins E6 and E7, 
which quickly inactivate several tumor suppressors and causes chemotaxis of various immune 
cells. E6 and E7 oncoproteins also interact with multiple host proteins and change their activity 
to enhance virus replication and persistence. This inadvertently induces cellular malignancy 
(Mallen-St Clair, et al., 2016). 
Vaccines 
There are currently three vaccines approved in the United States to prevent HPV and 
related illnesses (CDC, 2015). All three of the vaccines cover HPV strands 16 and 18, which are 
the agents known to cause cancers. HPV strands six and 11 are covered by two vaccines and 
these strands are the causative agent of HPV related genital warts. One of the vaccines that 
covers strands six and 11 also covers strands 31, 33, 45, 52, and 58, which have been found to 
cause cervical, vulvar, and vaginal diseases (WHO, 2016). 
Efficacy 
 The bivalent HPV vaccine (bHPVV) is effective against HPV strands 16 and 18, and is 
available for females aged ten to 25 (CDC, 2015). In females aged 15-25, the efficacy of the 
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vaccine in preventing cervical intraepithelial neoplasm (CIN2) is 94.9% and in preventing CIN3 
is 91.7%.  
The quadrivalent HPV vaccine (qHPVV) is effective against HPV strands 6, 11, 16, and 
18. It is available to females and males aged nine through 26 (CDC, 2015). In females aged 16-
26 year, qHPVV has an efficacy rate of 98.2% in preventing CIN2/3, 100% in preventing vulvar 
intraepithelial neoplasm (VIN) 2/3, and 99% in preventing genital warts. In males 16 to 26, 
qHPVV has an efficacy of 77.5% in preventing anal intraepithelial neoplasm (AIN).  
The third vaccine is the newest and is a nine valent HPV vaccine (9HPVV). 9HPVV 
protects against HPV strands six, 11, 16, 18, 31, 33, 45, 52, and 58. Studies related to the 
9HPVV are limited because it is relatively new. 9HPVV has shown to be non-inferior to qHPVV 
in preventing CIN and VIN in females ages 16 to 26, but was effective in preventing persistent 
infection and conditions related to HPV strands 31, 33, 45, 52, and 58 (Audisio, et al., 2016). 
Safety 
Local reactions, such as pain, redness, and swelling, are the most common side effects of 
both bHPVV and qHPVV. According to Audisio, et al. (2016), no serious adverse events have 
been found with either bHPVV or qHPVV. They found that pyrexia, headache, myalgia, and 
arthralgia have been reported. The WHO (2016) has reviewed reports on bHPVV and qHPVV 
and has determined that both vaccines have excellent safety and efficacy profiles.  
Prevalence  
In 2012, 28.1% of females aged 13 to 15 years had received all recommended doses of 
HPV vaccine (Healthy People 2020, 2016). According to the CDC (2015), the current rates for 
the HPV vaccine initiation in children 12 – 17 in the state of Kansas are less than 59% in girls 
and less than 39% in boys. The overall goal of Healthy People 2020 (2016) is to promote healthy 
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sexual behaviors, strengthen community capacity, and increase access to quality services to 
prevent sexually transmitted infections (STIs) and their complications. To reach this goal, 
Healthy People 2020 (2016) recommends that completion rate of the three dose HPV vaccine 
series is 80% in adolescent females aged 13 to 15 (Healthy People, 2016). 
Reason for Not Vaccinating 
 Of the articles review, 10 discussed the reasons why individuals were not receiving the 
HPV vaccine. Common themes found in this group include not enough education, side 
effect/safety, cost, no physician recommendation, and thoughts of being not at risk/or sexually 
active. 
Education 
Knowledge about HPV and the HPV vaccines is a modifiable risk factor that significantly 
contributes to under-vaccination. Nine articles reviewed found that one of the major reasons that 
vaccination rates are so low is due to a need for more education. Ratanasiripong (2012) and 
Small, Sampselle, Martyn, and Dempsey (2013) conducted systematic reviews that both found 
conflicting evidence related to the influence an educational deficit has on vaccinating. 
Ratanasiripong (2012) determined there is a direct relationship between knowledge and the intent 
to vaccinate. The lack of knowledge related to HPV and the HPV vaccine can result in 
misconception and negative attitudes toward the vaccine. 
 Researchers have examined why women 18 to 26 years of age are not vaccinating against 
HPV. Wilson, et al. (2016) found that 28% of the participants (n=325) who were not vaccinated 
wanted more information about the vaccine. The need for more education was the most common 
reason for not vaccinating in this study. Laz, Rahman, and Berenson (2013) found that 12.7% of 
the participants (n=1892) needed more information about the vaccine, which was the second 
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most common reason to decline vaccination. Schmidt and Parsons (2014) found that in 2008 
17% of participants (n=782) indicated they did not know enough about the vaccine, which 
dropped to 12% in 2012 (n=988).  
 Taylor et al. (2014) and Wong et al. (2011) surveyed mothers who had a daughter in the 
9-17 age range. Taylor et al. (2014) found that 43% of mothers (n=49) identified a lack of 
knowledge as their reason for not vaccinating their daughters against HPV. In a larger study by 
Wong, et al. (2011), 17.7% of participants (n=1105) identified a lack of knowledge as a reason 
for not vaccinating, which was the second most common reason to decline vaccination. 
 Oldach and Matz (2012) and Head, Vanderpool, and Mills (2013) used healthcare 
professional’s opinions to determine common reasons for refusal of the HPV vaccine. Oldach 
and Matz (2012) found that 55.6% of healthcare professionals (n=50) identified a lack of 
knowledge as a barrier to the vaccine, which was the most common reason in the study. In a 
smaller qualitative study of 15 healthcare professionals, one of two common themes for low 
HPV vaccine uptake was because patients did not think they needed the vaccine (Head, 
Vanderpool, & Mills, 2013). It was identified from the interviews that patients do not understand 
the link between HPV and cervical cancer, therefore identifying a knowledge deficit amongst 
these patients.  
Not at Risk/Sexually Active 
Nine articles were identified that indicated patient’s perception of not being at risk or not 
being sexually active as a reason for not vaccinating against HPV. Small, Martyn, and Dempsey 
(2013) performed a systematic review of literature and found that patient’s perception of risk was 
a significant contribution to not vaccinating, but did not indicate that sexual inactivity was a 
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factor. In a systematic review of literature, Ratanasiripong (2012) reported sexual inactivity as a 
significant reason for not vaccinating in women aged 18 – 26.  
 Young women aged 18-26 was the target population for multiple studies. An 
observational study (n=325) found that 10% of the study sample indicated not needing the 
vaccine due to sexual inactivity (Wilson, et al., 2016). Patel, et al., (2012) (n=80) found that not 
being at risk (28.8%) was the least common reasons found for not vaccinating against HPV. 
Schmidt and Parsons (2014) found both the perception of not being at risk and sexual inactivity 
as reasons for not vaccinating in their analysis of surveys from 2008 and 2010. In 2008, 35.9% of 
participants (n=782) indicated they did not need the vaccine, while only 10.3% of participants 
reported sexual inactivity as their reason for not vaccinating against HPV. In this study, 40.7% of 
participants (n=988) indicated not needing the vaccine and 8.1% of the participant’s reported 
sexual inactivity as their reason for not getting vaccinated against HPV in 2010. Another survey 
conducted in 2010 found that 39.6% of women aged 18-26 (n=1478) do not receive vaccinations 
against HPV because they do not think they need the vaccine (Laz, Rahman, & Berenson, 2013). 
 Parents of young girls aged nine to 17 indicated that their daughters did not need the 
vaccine or were sexually inactive in two studies. Taylor, et al. (2014) found 26% of parents 
(n=49) indicated this (n=49) as their reason for not vaccinating. A larger study found that 35.2% 
of parents (n=1105) indicated that their daughter does not need the vaccine or is not sexually 
active (Wong, et al., 2011). 
Side Effects/Safety 
Side effects and/or safety were reasons for not vaccinating in six articles reviewed. In a 
systematic review of literature by Small, et al. (2014), safety concerns influenced vaccine uptake 
in 24% of participants in three studies with a variety of populations including parents and young 
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women aged 18-26. Ratanasiripong (2012) found a wide range of < 5% - 42.9% of participants 
indicated safety concerns as a reason for not vaccinating in a systematic review. 
 A survey conducted in 2008 and 2010 found that 12.6 % of women age 26 years old were 
worried about the safety of the HPV vaccines (n=782) and 12.3% respectively (Schmidt & 
Parsons, 2014). Wilson, et al. (2016) found 13% of the 26 year old women (n=136) were 
concerned with safety and side effects. In a study of 26 year old female college students (n=80), 
48.8% of participants indicated concerns about safety and side effects as reasons they were not 
getting vaccinated against HPV (Patel, et al. 2012). Another study found 37.8 % of health care 
professionals (n=50) indicated that among parents of male and female adolescents their concerns 
about safety were barriers to HPV vaccination (Oldach & Katz, 2012). 
Cost 
The cost of the HPV vaccine can vary significantly due to variations in insurance 
coverage. Small, et al. (2014) found that cost and insurance coverage influenced young adult’s 
decision to vaccinate, but is less of a concern for the younger population. They indicated this 
difference is most likely because children 19 and younger are usually insured and may be 
eligible for free vaccines through the Vaccine for Children (VFC) program. 
 In a study of women 18-26 years of age (n=1892), cost was an issue for 2.6% of 
participants (Las, Rahman, & Berenson, 2012). This concern was highest in participants that did 
not have insurance (n=276; 5.3%). A survey of U.S. women age 18-26-years of age found that in 
2008 (n=782) and in 2010 (n=988) 1.8% and 2.5% participants indicated the HPV vaccine was 
too expensive (Schmidt & Parsons, 2014). In an observational study of college women (n=136), 
Wilson, et al. (2016) found that cost of the HPV vaccine was a main reason for not receiving the 
vaccine in 17% of participants (n=325). Patel, et al. (2012), who also studied college women, 
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found that cost of the vaccine was a significant concern to 41.3% of participants (n=80). A study 
of barriers reported by providers (n=45) found that 8.9% of providers find cost to be an issue in 
participants that do not qualify for the VFC program (Head, Vanderpool, & Mills, 2013). Cost 
was not a significant concern for parents of young girls between the ages of nine and 17 
(n=1105, 1.6%) (Wong, et al., 2011). 
Provider Recommendations  
If a provider does not recommend the HPV vaccine to patients, the uptake of the HPV 
vaccine can be affected. According to Small, et al. (2014), who performed a systematic review of 
literature, indicated that provider recommendation is one of the most clinically significant factors 
that has shown an increase in HPV vaccine uptake. A survey in 2008 (n=782) and 2010 (n=988) 
of U.S. women aged 18-26 found that no provider recommendation was the reasons 5.4% and 
7.4% women did not receive the HPV vaccine. Another survey on women aged 18-26 found that 
7.2% of participants (n=1892) did not get the HPV vaccine because their healthcare provider did 
not recommend it (Las, Rahman, & Berenson, 2012).  
 Taylor, et al. (2014) surveyed parents of girls aged nine to 17 (n=49) and found that 24% 
of participants reported no physician recommendation as their reason for not vaccinating their 
child. Another study of parents of young girls found that not receiving physician 
recommendation was less common of a reason to refuse the HPV vaccine. This study found that 
5.5% of parents refused the HPV vaccine due to not receiving physician recommendation for it 
(Wong, et al, 2011).  
Education Interventions 
 A limited number of studies used educational interventions as a variable to increase the 
initiation of the HPV vaccine series. A systematic review of literature conducted by Fu, 
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Bonhomme, Cooper, Joseph, and Zimet (2014) found educational trials directed toward parents, 
adolescence, and young adults did not show a significant increase in HPV vaccine uptake after 
intervention. Although these trials did not show significance, Fu, et al. (2014) concluded from 
their review that the intent of adolescents and young adults to receive the HPV vaccination could 
be influenced by education interventions. They also found that participants who received their 
initial HPV vaccine at the time of an educational intervention were more likely to complete the 
3-dose series. 
 Another systematic review found differing results related to the impact of educational 
interventions. They concluded that patient education showed a modest increase in the initiation 
of the HPV vaccine. They also found that interventions that were both provider and community 
based had the greatest impact on vaccine uptake (Smulian, Mitchell, & Stokley, 2016).  
Summary 
Although there is not strong evidence indicating educational interventions will greatly 
affect the initiation of the HPV vaccine series, education related to HPV vaccine is needed. Of 
the reasons indicated for not receiving the HPV vaccine, not enough education, side 
effects/safety, and perception of not being at risk or sexually active are possible reasons where 
educating patients about HPV and the HPV vaccine could change their decision concerning 
vaccinations. 
With the consistent rise in individuals infected with HPV, it is important that 
interventions to increase vaccination rates be pursued. As vaccination rates increase, the risk of 
acquiring an HPV related cancers or illnesses would begin to decrease. The goal of Health 
People 2020 is an 80% vaccination rate, which will require interventions to increase compliance 




Current literature suggests that there is a knowledge deficit pertaining to HPV and the 
HPV vaccine. Although there is no specific intervention that has shown an increase in the uptake 
of the HPV vaccine, there are studies that show educational interventions do increase the intent 
to vaccine and improve overall knowledge about HPV and the HPV vaccine.  
The aim of this quality improvement (QI) project is to increase the number of HPV 
vaccines given to young adults (ages 18-26 years old) through an educational pamphlet related to 
HPV and the HPV vaccines. The project question developed is: Will the use of an education 
pamphlet on HPV and the HPV vaccines increase the initial uptake of the HPV vaccine in young 
adults aged 18-26? The Project Director assumes that providing an educational pamphlet to 
young adults before they see their health care provider will increase the number of HPV vaccines 
administered at ComCare in Salina, Kansas. 
Theoretical Framework 
 The Plan-Do-Study-Act (PDSA) framework was chosen for this QI project. The purpose 
of the PDSA framework is to establish a functional relationship between process changes in 
systems of healthcare and variations in outcomes (Speroff & O’Connor, 2004). By following this 
framework, the question “How will we know that a change is an improvement?” will be 
answered (Speroff & O’Connor, 2004).  
 The PDSA model is a four-stage cyclic learning approach. The model mirrors the 
scientific method and is used to adapt changes aimed at improvement. This framework follows 
four major steps. Taylor, et. al (2013) describe the steps as: “In the ‘plan’ stage a change aimed 
at improvement is identified, the ‘do’ stage sees this change tested, the ‘study’ stage examines 
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the success of the change and the ‘act’ stage identifies adaptations and next steps to inform a new 
cycle” (Taylor, McNicholas, Nicolay, Darzi, Bell, & Reed, 2013) (p. 291).  
Following the PDSA framework, a plan was developed for this QI project. The change 
that this project evaluated is the use of educational pamphlets about HPV and the HPV vaccine at 
ComCare in Salina, Kansas. The goal of the project was to increase the HPV vaccine in young 
adults aged 18-26 by educating them on HPV and the HPV vaccine. To determine if the use of 
educational pamphlets made an improvement in vaccine uptake, providers within the clinic 
completed pre- and post-intervention surveys. After data were collected, the Project Director 
reviewed the surveys and interrupt the data to determine if the use of educational pamphlets 
increased the uptake of the HPV vaccine. The findings were shared with the healthcare providers 
at ComCare.  
Definitions 
Conceptual Definition: Educational Information 
 An educational pamphlet is a document that provides the reader with general information 
about a specific subject. Educational information should be designed to improve patient 
knowledge or attitude (Fu, et al., 2014). Educational information is defined by Patel, el al. 
(2013), as a fact sheet that is molded from information from the CDC.  
Operational Definition: Education Information 
For this QI project, the education information will be provided in the form of an 
educational pamphlet. The pamphlets are a single sheet of paper, both front and back, in an easy 
to read format. Information about HPV and the HPV vaccine was obtained from the CDC and 
the Immunization Action Coalition. There was also input from four different content experts, 
consisting of one Physician and three Nurse Practitioners.  
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Conceptual Definition: Young Adult 
 Young adults can be defined as individuals, both male and female, between the ages 20 – 
26 (Fu, et al., 2014). This age group of individuals are usually at a higher risk for STIs due to a 
combination of behavior, biological, and cultural reasons.  
Operational Definition: Young Adult 
For this QI project, a young adult is defined as any male or female between the ages of 18 
and 26. There will be no regulations related to ethnicity. This age group was chosen because at 
the age of 18 individuals can make informed consent. The HPV vaccine can be administered to 
individuals up until the age of 26 years old, so this allow all individuals who are able to make 
informed consent and receive the vaccine be included in the study. 
Conceptual Definition: Initial dosage 
Patel, et al. (2012) defined the initial dosage as receiving the first dose of the vaccine 
series. The participant cannot have received a dose of the HPV vaccine within their lifetime.  
Operational Definition: Initial dosage  
The initial dosage for this QI project will be defined as receiving at least one dose of the 
HPV vaccine series. For this QI project, there will be no requirements related to time of initial 
dose or uptake of subsequent doses.  
Methods 
Design 
 This project is an evidence based QI project. The Institutional Review Board at the 
University of Kansas Medical Center reviewed the protocol and gave permission to perform this 
QI project (Appendix D). Management at ComCare in Salina, Kansas was contacted about this 
QI project and provided the Project Director a letter of approval (Appendix G) to perform this QI 
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project. Prior to distribution of the pre-survey, providers at ComCare were sent a letter 
(Appendix E) informing them about this QI project and asking them for their participation in this 
QI project. 
Providers at ComCare in Salina, Kansas were given a pre-survey (Appendix B), to 
determine how many HPV vaccines they recommend, how many HPV vaccines are provided, 
reasons for patient refusal of the HPV vaccine, and patient demographics. After the pre-survey 
was completed, educational pamphlets (Appendix F) were distributed. These educational 
pamphlets include information about HPV and the HPV vaccine from evidence based and 
accredited websites, such as the CDC, as well as input from four different content experts. These 
experts consist of a one Physician and three Nurse Practitioners. The pamphlets were placed in 
the waiting room and examination rooms of the clinic. Once a week the Project Director ensured 
there were adequate amounts of pamphlets available to patients and answered any questions 
providers had.  
After a six–week period, providers were asked to complete the post-survey (Appendix C) 
to determine if there were changes in the number of HPV vaccines recommended, number of 
HPV vaccines provided and/or the reasons for not vaccinating. Providers were also asked if they 
felt the educational pamphlets were beneficial to their practice.  
Project Sample and Selection  
 The sample consisted of ten healthcare providers working at ComCare. The healthcare 
providers consisted of eight Physicians and two Nurse Practitioners who practice at the clinic.   
Data Collection 
Data were collected through pre- and post-surveys completed by the healthcare providers 
at ComCare. The information collected includes estimated number of HPV vaccines 
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recommended each week, estimated number of HPV vaccines given each week, reasons patients 
refuse the vaccine, age range of patients receiving the vaccine, sex of patients receiving the 
vaccine, and ethnicity of patients receiving the vaccine. The surveys the providers at ComCare 
completed include no identifying data to maintain confidentiality of the patients and providers. 
Results 
 Nine out of 10 providers chose to participate in the pre-survey and eight out of 10 
providers participated in the post-surveys. Frequency of answers to the survey questions are 
displayed in tables, bar charts, and pie charts. Demographic data were analyzed and all of the 
providers reported on both the pre- and post-surveys that the most common patients they met in 
the study population were white females between the ages of 18 and 22.  
 The first question of the surveys asked the providers on average, how many patients do 
you see in the clinic each week that are between the ages 18 and 26? Figure 1 (Appendix H) 
shows the number of providers that responded for each option. The pre-survey showed that six 
providers (66%) reported that they met nine or more patients between the ages of 18 and 26 each 
week. On the post-survey showed five providers (63%) met nine or more patients between the 
ages of 18 and 26 each week. There was one provider in the clinic that met zero to two patients. 
One provider met three to five patients and one provider that met six to eight patients between 
the ages of 18 and 26 each week in both the pre- and post-surveys. 
On the pre-survey, eight of the providers (89%) reported that zero to two of the patients 
they met each week had already initiated the HPV vaccine (Figure 2, Appendix H). Only one 
provider (11%) reported more than this, and they reported examining three to five of the patients 
each week that had already initiated the HPV vaccine. All nine providers, 100 % of providers, 
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reported on the pre-survey that they have zero to two patients which initiated the vaccine each 
week (Figure 3, Appendix H). 
Figure 2 also shows the post survey results for the number of providers that had patients 
who had already initiated the HPV vaccine. Three of the providers (37.5%) reported they had 
three to five patients a week that had initiated the HPV vaccine series, while five (62.5%) 
providers, reported zero to two patients had initiated the HPV vaccine series. During the post 
survey, providers had more patients initiate the HPV vaccine series than in the pre-survey 
(Figure 3, Appendix H). Two providers (25%) reported that six to eight of their patients initiated 
the vaccine series a week, while six providers (75%) reported zero to two patients initiated the 
HPV vaccine each week.  
 Providers were asked to report reasons their patient refused the HPV vaccine. The most 
common reasons patients refuse the vaccine, from the literature review, include education deficit, 
cost, side effects/safety, and fear of shots. Providers were to choose all of the reasons that apply 
to their practice and Figure 4 (Appendix H) illustrates these results. The most common reason 
for refusal of the HPV vaccine was an educational deficit. At ComCare, 89% of providers 
indicated this as a reason their patients refused the HPV vaccine. Another common reason for 
refusal was concerns about side effects or safety, where 56% of providers indicated this as a 
reason for vaccine refusal. There were 33% of providers indicating the cost of the vaccine was a 
concern for patients and 22% of providers indicated that their patients had a fear of shots.  
 During the post survey, providers were asked if they felt the educational pamphlet that 
had been placed throughout the ComCare clinic was beneficial in their care for young men and 
women aged 18 to 26. The results of this question showed that 62% of providers thought the 
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pamphlet was beneficial, 29% of providers thought that the pamphlet was not beneficial, and 
14% of providers were not sure if they were beneficial (Figure 5, Appendix H). 
Discussion 
Overall, the response rate of the providers was excellent. There was a small sample size 
of 10 providers, but 90% of them responded to the pre-survey and 80% responded to the post-
surveys. Between 63% and 66% of providers examined nine or more patients each week that met 
criteria for this QI project, which included that the patient being a male or female between the 
ages of 18 and 26. 
The provider responses to reasons why patients were refusing the HPV vaccine in this QI 
project were similar to those found in literature. Oldach and Matz (2012) interviewed healthcare 
professionals and found the most common reason for vaccine refusal was due to an educational 
deficit. They found 55.6% of healthcare professionals identified educational deficit as the main 
reason for not vaccinating. A systematic review of literature by Ratanasiripong (2012) also found 
that the main reasons patients were refusing the HPV vaccine series was due to an educational 
deficit. The results of this QI project showed that educational deficit was the most common 
reason for HPV vaccine refusal as indicated by the healthcare providers participating in the 
survey. This QI project showed that 89% of providers identified an education deficit in their 
patients as the reason for vaccine refusal.  
Patel, et al. (2012) found that 48.9% of women age 18 – 26 years of age were concerned 
of side effects and safety, which is comparable to the result of 56% reported by providers in this 
QI project. In this QI project, cost was the second most common reasons providers identified for 
patients not vaccinating against HPV. Oldach and Katz (2012) also determined safety and side 
effects were the second most common reason for not vaccinating against HPV in their study of 
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providers. They concluded that 37.8% of providers identified safety and side effects as a 
concern. While safety and side effects are concerns in multiple studies, it has been identified that 
all of the HPV vaccines have a low risk safety profile and high efficacy rates in preventing a 
variety of cancers.  
Cost of the vaccines were identified as the third most common reason for not vaccinating 
in this QI project. It was determined that 33% of providers in this QI project identified cost as a 
barrier to patients receiving the HPV vaccine. Small, et al. (2012) found, in a systematic review 
of literature, cost influenced patient’s intent to vaccinate. They found this to be a bigger concern 
for young adults than adolescence. Patel et al. (2012) identified cost as a barrier and indicated 
that 41.3% of college women who participated in their study reported cost as a reason for not 
vaccinating. Wilson, et al. (2016), who also studied college aged women, found that 17% of 
participants identified cost as a concern related to receiving the HPV vaccine. Head, Vanderpool, 
and Mills (2013) found that 8.9% of providers identified cost as a barrier to patients receiving the 
HPV vaccine. When looking at studies of similar age groups, the results of this QI project are 
comparable to current literature.  
The results of this QI project showed a slight increase in the number of patients that had 
started the HPV vaccine series and the number of HPV vaccines given each week. These results 
correlate to those concluded by Smulian, Mitchell, and Stokley (2016), who determined there 
was a modest increase in the initiation of the HPV vaccine with patient education. The results of 
this QI project differ from those found by Fu, et al. (2014), who found that educational trails for 
parents, adolescents, and young adults did not show significant increase in HPV vaccine uptake. 
However, these researchers did identify the intent to vaccinate increased in young adults when 
they were educated about HPV and the HPV vaccine.  
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The results of this QI project showed a slight increase in the number of patients that had 
started the HPV vaccine series and the number of HPV vaccines given each week. These results 
correlate to those concluded by Smulian, Mitchell, and Stokley (2016), who determined there 
was a modest increase in the initiation of the HPV vaccine with patient education. The results of 
this QI project differ from those found by Fu, et al. (2014), who found that educational trails for 
parents, adolescents, and young adults did not show significant increase in HPV vaccine uptake. 
However, these researchers did identify the intent to vaccinate increased in young adults when 
they were educated about HPV and the HPV vaccine.  
Limitations 
This QI project, using educational pamphlets to increase the uptake of the HPV vaccine, 
was performed over a six-week period. The results did show a slight increase in the number of 
patients who received the HPV vaccine, but it is unknown if the educational pamphlets were the 
specifically related to this increase. Conducting a longer study would be beneficial to help 
determine if the educational pamphlets assisted with the significant increase in HPV 
vaccinations. The sample of young adults that was sampled in this QI project was mainly white 
females between the ages of 18 and 22, which does not fully represent the population available to 
receive this vaccine. It would be beneficial to perform similar projects in a more diverse 
population.  
 The surveys used in this QI projects used ranges for the number of patients each provider 
cared for, the number of patients who had previously initiated the HPV vaccine, and the number 
of patients who initiated the HPV vaccine each week. The results of these questions could be 
more precise if whole numbers were used instead of ranges. In addition, providers estimated the 
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number of patients they cared for related to each of these questions. The results would be more 
precise if data were collected through chart review instead of provider recall and estimations. 
 While this QI project was intended to educate young adults aged 18 to 26, interventions 
should also look at ways to educate parents and adolescence. Patients should be receiving the 
HPV vaccine prior to exposure to HPV, which would be prior to sexual activity. Today the age 
of first sexual activity is becoming younger. Irala, Osorio, Ruiz-Canela, and Lopez-del Gurgo 
(2011) found that in the United States the mean age for first sexual intercourse is age 15. Thus, 
intervention for young adults may come too late to prevent HPV and HPV related diseases for all 
that vaccinate during this age.  
Conclusion 
 The educational pamphlets showed to be beneficial in this clinic setting. The results of 
this QI project showed that there was a slight increase in the number of patients who received the 
HPV vaccine after the educational pamphlets were made available. This QI project identified 
that, according to providers, there is a significant educational deficit in patients related to HPV 
and the HPV vaccine. Providers in this clinic setting concluded that educational pamphlets were 
beneficial to their care related to HPV in young adults aged 18 to 26. 
Recommendations for Practice 
  As the incidence rates of HPV infections and related cancers continues to rise, it is 
important that providers can identify ways to decrease rates. Patient education has been 
identified as a major deficit related to HPV. The HPV vaccine is just one topic that providers 
need to educate patients on related HPV prevention. Other topic that should be discussed with 
patients include abstinence, limiting sexual partners, and the use of condoms. Studies should 
26 
 
continue to be developed to asses if other educational interventions would be more beneficial 
than an educational pamphlet.  
 Research should continue to determine age specific intervention that will help educate 
parents, adolescents, and young adults. Technology has become a part of everyday life and 
should be used as a tool to educate patients. Further research should be done to determine if 
educational interactive digital programs on tablets in the waiting room or educational clips 
delivered on tablets or televisions in waiting rooms would increase patient’s knowledge about 
HPV and the HPV vaccine.  
 The overall rates of HPV vaccination are low; therefore, interventions that are not age 
specific should be researched as well. Other methods to increase the uptake of the HPV vaccine 
that should be investigated to include an incentive gift for receiving the vaccine or a free 
vaccination day. While it was not the top reason for not vaccinating, the cost of the vaccine was 
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1. On average, how many patients do you see in the clinic each week that are between the ages 
18 and 26? 
 a. 0-2 
 b. 3-5 
 c. 6-8 
 d. 9 or more 
2. How many of these patients, men and women aged 18 to 26, that you see each week, have 
initiated the Human Papilloma Virus (HPV) vaccine series? 
a. 0-2 
 b. 3-5 
 c. 6-8 
 d. 9 or more 
3. Approximately how many HPV series are initiated each week to patients between of ages of 
18 to 26? 
a. 0-2 
 b. 3-5 
 c. 6-8 
 d. 9 or more 
 
4. What are the reasons patients refused the HPV vaccine? (Please Circle all that apply) 
 Educational deficit        Cost        Side effects/Safety       Fear of Shots 
 
5. What are the most common demographic categories of the patients that have received the HPV 
vaccine series in your practice? (Circle One for each category below) 
 Age Ranges in years:  18 – 22 y/o    23 – 26 y/o 
 Gender:   Female    Male 
 Race:    White     African American       Hispanic      Asian       Other 
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Post-intervention Survey 
1. On average, how many patients do you see in the clinic each week that are between the ages 
18 and 26? 
 a. 0-2 
 b. 3-5 
 c. 6-8 
 d. 9 or more 
2. How many of these patients, men and women aged 18 to 26, that you see each week, have 
initiated the Human Papilloma Virus (HPV) vaccine series? 
a. 0-2 
 b. 3-5 
 c. 6-8 
 d. 9 or more 
3. Approximately how many HPV series are initiated each week to patients between the ages of 
18 and 26? 
a. 0-2 
 b. 3-5 
 c. 6-8 
 d. 9 or more 
 
4. What are the reasons patients refused the HPV vaccine? (Please Circle all that apply) 
 Educational deficit         Cost        Side effects/Safety       Fear of Shots 
 
5. Do you feel that the pamphlets were beneficial to your care related to HPV in young men and 
women aged 18 to 26? 
  a. Yes     
b. No  
 
6. What are the most common demographic categories of the patients that have received the HPV 
vaccine series in your practice? (Circle One for each category below) 
 Age Ranges in years:  18 – 22 y/o    23 – 26 y/o 
 Gender:   Female    Male 
 Race:    White     African American       Hispanic      Asian       Other  
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Alternate Contact Person (e.g., Project Coordinator): Julie R. Jennings 
Email: jjennings2@kumc.edu Phone: 620-290-2210 
 
Project Title:  
 
INCREASING HUMAN PAPILLOMAVIRUS VACCINATION IN YOUNG ADULTS 
 
 




1. Briefly state the purpose of the proposed project. (Attach project plan if available.) 
 
The aim of this quality improvement project will be to increase the number of HPV 
vaccines given to young adults (ages 18-26) through an educational pamphlet related to 
HPV and the HPV vaccines. The Project Director assumes that providing an educational 
pamphlet to young adults before they see their health care provider will increase the 
number of HPV vaccines administered at ComCare in Salina, Kansas. 
 
2. Describe the research that has already demonstrated the effectiveness of your 
intervention. (Cite research and/or attach documentation about the national program or 
standard you are implementing) 
The goal of Health People 2020 is an 80% vaccination rate, which will require interventions 
to increase compliance with CDC recommendations related to the HPV vaccine. 
KUMC HUMAN SUBJECTS COMMITTEE 
 
REQUEST FOR  
QUALITY IMPROVEMENT/QUALITY ASSURANCE DETERMINATION 
 
*THIS FORM MUST BE TYPED* 
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Ratanasiripong (2012) determined there is a direct relationship between knowledge and the 
intent to vaccinate and the lack of knowledge related to HPV and the HPV vaccine can result 
in misconception and negative attitudes toward the vaccine. Laz, Rehman, and Berenson 
(2012) found that in 2010, 39% of women participants aged 18- 26 did not get the HPV 
vaccine because they did not need the vaccine and 12.7% of women participants did not get 
the vaccine because they needed more information. Wilson, et al. (2016) also found that 28% 
of study participants did not receive the HPV vaccine because they needed more information. 
Knowledge deficits seemed to be a large issue related to not vaccinating for HPV throughout 
the literature. Smulian, Mitchell, and Stokley (2016) concluded that patient education showed 
a modest increase in the initiation of the HPV vaccine. Although there is not strong evidence 
indicating educational interventions will greatly impact the initiation of the HPV vaccine 
series, it is evident that there is a need for education related to HPV and the HPV vaccine.  
 
3. What types of data are needed for the project?  
This QI project will consist of qualitative data that are collected from a survey. The data 
will include information about providers’ recommendation and administration of the 
HPV vaccine, reasons seen for refusal of the vaccine, and patient demographics. 
 
4. Do you need access to identifiable patient records to complete the project?   
 
X  NO 
  YES 
 
 If yes, who holds the records?       
 
 If yes, which patient identifiers or demographics are needed for the project?  
      
 
 
5. Which descriptions best fits your project? Check all that apply: 
 
  Determine if a previously implemented clinical practice improved the quality of patient 
care  
  Evaluate or improve the local implementation of widely accepted clinical or educational 
standards that have been proven effective at other locations  
 Gather data on hospital or provider performance for clinical, practical or administrative 
uses 
  Conduct a needs assessment to guide future changes in local health care delivery or to 
support other improvements at KUMC 
  Perform an analysis to characterize our patient population/clients to improve quality of 
services  
  Implement programs to enhance professional development for providers and trainees 
X Measure local efficiency, cost or satisfaction related to standard clinical practices 
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X  Develop interventions or educational strategies that improve the utilization of recognized 
best practices 
X Implement strategies to improve communication within our local healthcare environment 
X  Improve tools for patients that promote education, health literacy or treatment plan 
compliance  
 
6. Does your project involve any of the following aspects? Check all that apply: 
 
 Randomizing participants into two or more groups  
 Student/residents/trainees are randomized  
Patients are randomized 
Healthcare providers are randomized  
Units of the hospital are randomized  
  Other  Specify:       
 
X Surveying a patient population  
X Developing clinical practice guidelines 
 Developing new curriculum recommendations 
 Developing or refining a new assessment tool 
X Implementing a novel approach to care that may improve patient outcomes  
 
 
7. Which institutions are involved in the project? 
KUMC only 
Other institutions  List ComCare 
 
 
8. Which individuals or groups will receive the results of your project?  
Internal department personnel 
Hospital representatives  
  University representatives 
X  Presentation/publication* 
  Other  Specify       
 
 
9. How will your results be used to implement local improvements?  
If the pamphlets are determined to be beneficial, they will be implemented on a long-term 
basis at the clinic.   
 
 
_______________________________________   ____________________ 
Signature**        Date 









*Any presentation or publication resulting from this project should explicitly state that it was 
undertaken as quality improvement.  
 
 






FOR OFFICE USE ONLY 
 





_______________________________________    ______________ 
Signature              Date 
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Appendix E 
ComCare 
520 S. Santa Fe Ave Suite 300 
Salina, KS 67401 
 
 
To whom it may concern, 
 
I am a Family Nurse Practitioner student at The University of Kansas Medical Center. I am 
contacting you because you are a provider at ComCare in Salina, Kansas. I am recruiting 
participants to help in a quality improvement project to increase the administration of the Human 
Papillomavirus vaccine for young adults aged 18-26. I have developed an educational pamphlet 
using information from medical websites, as well the input of four medical professionals. The 
pamphlet will be placed in the waiting room of the clinic for patients to read as they wait to see 
their provider.  
 
Participation in this quality improvement project involves completing a pre-and post-intervention 
survey that will take approximately 3 – 5 minutes. I am seeking your participation is this survey. 
No identifiable information will be collected about you or your patients and the survey is 
anonymous. There are no personal benefits or risks to participating in this survey. Participation is 
voluntary and you can stop taking the survey at any time. You will be notified when the surveys 
are available at the clinic. 
 
If you have any questions, please contact Julie Jennings at (620) 290-2219 or 
jjennings2@kumc.edu. For questions about the rights of research participants, you may contact 




Julie R. Jennings, RN, BSN 
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APPENDIX F 
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Appendix G 
 




On average, how many patients do you see in the clinic each week that are between the ages 
18 and 26? 
  Pre-survey Post-survey 
 A. 0 – 2 1 1 
 B. 3 – 5 1 1 
 C. 6 – 8 1 1 
 D. 9 or more 6 5 
 Figure 1: Question 1    
How many of these patients, men and women age 18 to 26, that you see each week, have 
initiated the HPV vaccine series? 
  Pre-survey Post-survey 
 A. 0 – 2 8 5 
 B. 3 – 5 1 3 
 C. 6 – 8 0 0 
 D. 9 or more 0 0 
 Figure 2: Question 2   
Approximately how many HPV series are initiated each week to patients between the ages of 
18 and 26? 
  Pre-survey Post-survey 
 A. 0 – 2 9 6 
 B. 3 – 5 0 0 
 C. 6 – 8 0 2 
 D. 9 or more 0 0 
 Figure 3: Question 3   






























Reasons for vaccine refusal 




Do you feel the pamphlets were beneficial to your 
care related to HPV in young men and women 




Figure 4: Reasons for vaccine refusal 
Figure 5: Post-survey Question 5 
